Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Mainz Biomed NV - SIC # 8071 - MEDICAL LABORATORIES
Ticker
Exchange
SIC #
Website
Latest Ticker
MYNZ
Nasdaq
8071
https://www.mainzbiomed.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Mainz Biomed NV
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
- Apr 25th, 2024 1:29 pm
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
- Apr 10th, 2024 4:47 pm
Mainz Biomed Reports Full Year 2023 Financial Results
- Apr 9th, 2024 12:01 pm
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
- Mar 19th, 2024 12:01 pm
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
- Mar 18th, 2024 12:01 pm
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
- Mar 12th, 2024 12:01 pm
What Makes Mainz Biomed NV (MYNZ) a New Buy Stock
- Mar 8th, 2024 5:00 pm
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
- Mar 5th, 2024 1:01 pm
Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening
- Feb 28th, 2024 5:54 pm
Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
- Feb 27th, 2024 1:01 pm
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
- Feb 22nd, 2024 7:21 pm
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
- Feb 22nd, 2024 1:01 pm
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
- Feb 21st, 2024 1:01 pm
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
- Feb 7th, 2024 5:13 pm
Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
- Feb 6th, 2024 1:01 pm
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
- Feb 1st, 2024 9:17 pm
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
- Jan 11th, 2024 1:01 pm
2024 Marks a New Era Of Pharmaceutical Innovation
- Jan 9th, 2024 8:40 pm
Mainz Biomed Provides Year-End Corporate Review 2023
- Jan 9th, 2024 1:01 pm
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
- Dec 29th, 2023 7:48 pm
Scroll